Recently, Keylights (Shenzhen) Technology Co., LTD. (hereinafter referred to as Keylights) announced the completion of nearly 100 million yuan of series B financing, which was led by Lucion Venture Capital, and followed by Hanchi Venture Capital. After the financing, Keylights will further accelerate the commercialization of a full range of chemiluminescence, immunofluorescence, molecular diagnosis and other in vitro diagnostic instruments, provide ultra-stable, high-performance, cost-effective products and CDMO services for both domestic and international customers, and become the leading independent brand of in vitro diagnostic instruments and global suppliers for CDMO.